219 related articles for article (PubMed ID: 37175654)
21. Neuroinflammation and Autophagy in Parkinson's Disease-Novel Perspectives.
Minchev D; Kazakova M; Sarafian V
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499325
[TBL] [Abstract][Full Text] [Related]
22. Intranasal PRGF-Endoret enhances neuronal survival and attenuates NF-κB-dependent inflammation process in a mouse model of Parkinson's disease.
Anitua E; Pascual C; Pérez-Gonzalez R; Orive G; Carro E
J Control Release; 2015 Apr; 203():170-80. PubMed ID: 25702964
[TBL] [Abstract][Full Text] [Related]
23. Parkinson's disease: Autoimmunity and neuroinflammation.
De Virgilio A; Greco A; Fabbrini G; Inghilleri M; Rizzo MI; Gallo A; Conte M; Rosato C; Ciniglio Appiani M; de Vincentiis M
Autoimmun Rev; 2016 Oct; 15(10):1005-11. PubMed ID: 27497913
[TBL] [Abstract][Full Text] [Related]
24. Neuronal vulnerability in Parkinson's disease.
Double KL
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S52-4. PubMed ID: 22166454
[TBL] [Abstract][Full Text] [Related]
25. Pomegranate juice exacerbates oxidative stress and nigrostriatal degeneration in Parkinson's disease.
Tapias V; Cannon JR; Greenamyre JT
Neurobiol Aging; 2014 May; 35(5):1162-76. PubMed ID: 24315037
[TBL] [Abstract][Full Text] [Related]
26. Classic and evolving animal models in Parkinson's disease.
Pingale T; Gupta GL
Pharmacol Biochem Behav; 2020 Dec; 199():173060. PubMed ID: 33091373
[TBL] [Abstract][Full Text] [Related]
27. A Focus on Astrocyte Contribution to Parkinson's Disease Etiology.
Prunell G; Olivera-Bravo S
Biomolecules; 2022 Nov; 12(12):. PubMed ID: 36551173
[TBL] [Abstract][Full Text] [Related]
28. l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease.
Billings JL; Gordon SL; Rawling T; Doble PA; Bush AI; Adlard PA; Finkelstein DI; Hare DJ
J Neurochem; 2019 Jul; 150(1):88-106. PubMed ID: 30716176
[TBL] [Abstract][Full Text] [Related]
29. Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications.
Wilms H; Zecca L; Rosenstiel P; Sievers J; Deuschl G; Lucius R
Curr Pharm Des; 2007; 13(18):1925-8. PubMed ID: 17584117
[TBL] [Abstract][Full Text] [Related]
30. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R
Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932
[TBL] [Abstract][Full Text] [Related]
31. Cellular and molecular pathophysiology in the progression of Parkinson's disease.
Zaman V; Shields DC; Shams R; Drasites KP; Matzelle D; Haque A; Banik NL
Metab Brain Dis; 2021 Jun; 36(5):815-827. PubMed ID: 33599945
[TBL] [Abstract][Full Text] [Related]
32. Neuroinflammation and protein pathology in Parkinson's disease dementia.
Kouli A; Camacho M; Allinson K; Williams-Gray CH
Acta Neuropathol Commun; 2020 Dec; 8(1):211. PubMed ID: 33272323
[TBL] [Abstract][Full Text] [Related]
33. Inflammatory neuronal loss in the substantia nigra induced by systemic lipopolysaccharide is prevented by knockout of the P2Y
Milde S; van Tartwijk FW; Vilalta A; Hornik TC; Dundee JM; Puigdellívol M; Brown GC
J Neuroinflammation; 2021 Oct; 18(1):225. PubMed ID: 34635136
[TBL] [Abstract][Full Text] [Related]
34. Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons.
Dragicevic E; Poetschke C; Duda J; Schlaudraff F; Lammel S; Schiemann J; Fauler M; Hetzel A; Watanabe M; Lujan R; Malenka RC; Striessnig J; Liss B
Brain; 2014 Aug; 137(Pt 8):2287-302. PubMed ID: 24934288
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
[TBL] [Abstract][Full Text] [Related]
36. Does vitamin D protect or treat Parkinson's disease? A narrative review.
Al-Kuraishy HM; Al-Gareeb AI; Selim HM; Alexiou A; Papadakis M; Negm WA; Batiha GE
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; 397(1):33-40. PubMed ID: 37555855
[TBL] [Abstract][Full Text] [Related]
37. Constitutively active STING causes neuroinflammation and degeneration of dopaminergic neurons in mice.
Szego EM; Malz L; Bernhardt N; Rösen-Wolff A; Falkenburger BH; Luksch H
Elife; 2022 Oct; 11():. PubMed ID: 36314770
[TBL] [Abstract][Full Text] [Related]
38. Cannabidiol Alleviates the Damage to Dopaminergic Neurons in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinson's Disease Mice Via Regulating Neuronal Apoptosis and Neuroinflammation.
Wang L; Wu X; Yang G; Hu N; Zhao Z; Zhao L; Li S
Neuroscience; 2022 Aug; 498():64-72. PubMed ID: 35792194
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic potential of ATP-sensitive potassium channels in Parkinson's disease.
Zhao S; Wang M; Ma Z
Brain Res Bull; 2021 Apr; 169():1-7. PubMed ID: 33434622
[TBL] [Abstract][Full Text] [Related]
40. Neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson's disease mice.
Karikari AA; McFleder RL; Ribechini E; Blum R; Bruttel V; Knorr S; Gehmeyr M; Volkmann J; Brotchie JM; Ahsan F; Haack B; Monoranu CM; Keber U; Yeghiazaryan R; Pagenstecher A; Heckel T; Bischler T; Wischhusen J; Koprich JB; Lutz MB; Ip CW
Brain Behav Immun; 2022 Mar; 101():194-210. PubMed ID: 35032575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
